Marker Therapeutics, Inc.

Daily Archives: Tuesday, February 7, 2017

TapImmune Expands Intellectual Property On PolyStartTM Platform For Use In Next-Generation T-Cell Vaccines

TapImmune, Inc. (NASDAQ: TPIV) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application titled, “Chimeric nucleic acid molecules with non-AUG initiation sequences and uses thereof.”

Read More